Irbesartan Stada

Irbesartan, the active ingredient in Irbesartan Stada, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable supply chains, comprehensive documentation, and responsive technical support.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect renal function.

Hypertension: reduces systemic vascular resistance and lowers blood pressure. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Proteinuria in diabetic patients: decreases urinary protein excretion, contributing to renal protection.

Irbesartan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Abdominal discomfort - Cough

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hyperkalemia - Acute renal failure or worsening kidney function - Hepatic injury (elevated liver enzymes, jaundice)

When prescribing Irbesartan, clinicians should observe several safety considerations.

Monitor blood pressure: check regularly to ensure therapeutic effect. Monitor renal function: assess serum creatinine and eGFR before and during therapy. Monitor serum potassium: detect hyperkalemia, especially with potassium‑sparing agents. Avoid use in pregnancy: drug is contraindicated due to fetal toxicity (Category D). Use caution in hepatic impairment: dose adjustment may be required. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients. - Dual therapy with ACE inhibitors or other ARBs. - Potassium‑sparing diuretics (e.g., spironolactone, amiloride). - Lithium (may increase serum levels).

Moderate Interactions (Monitor Closely): - NSAIDs (risk of renal impairment). - Thiazide diuretics (enhanced hypotensive effect). - Cyclosporine (may increase serum creatinine). - Rifampin (may reduce plasma concentration of Irbesartan).